Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC0705-0002 · NNC0705

Other · developed by Novo Nordisk

Phase 1 Most advanced trial
NVO Developer

What is NNC0705-0002?

NNC0705-0002 is an oral capsule formulation. It is studied in healthy volunteers and in cardiometabolic diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC0705
Drug type
Other
Therapy area
Metabolic
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Cardiometabolic DiseasesHealthy Volunteers

More from Novo Nordisk

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind NNC0705-0002

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.